Patients with trisomy 21 [Down syndrome (DS)]
INTRODUCTION
Alzheimer's disease (AD) is characterized by the progressive deposition of extracellular amyloid in brain parenchyma and meningocerebral blood vessel walls. The amyloid consists of heterogeneous amyloid b-peptides (Ab) of various lengths proteolytically derived from the b-amyloid precursor protein (bAPP). Because the bAPP gene is encoded on chromosome 21 and is overexpressed in trisomy 21 [Down syndrome (DS)], DS provides a compelling model for examining in temporal fashion the pathological changes that occur in Alzheimer's disease. The bAPP gene is en-
